Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, . . . Bruno Cenni. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Wiley.
Chicago Style (17th ed.) CitationMartin Kaul, et al. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Wiley, 2021.
MLA (9th ed.) CitationMartin Kaul, et al. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Wiley, 2021.
Warning: These citations may not always be 100% accurate.